Topiramate in the treatment of neuropathic pain in patients with cancer

Edmond A. Bendaly, Carol A. Jordan, Sandra S. Staehler, Daniel A. Rushing

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Neuropathic pain has been reported to affect 40%-50% of patients with cancer. Patients and Methods: Consecutive patients selected from the outpatient/adult patient palliative care clinic of the Roudebush Veterans Affairs Medical Center and the Indiana University Palliative Clinic were reviewed. A verbal pain linear analogue assessment scale was used to assess neuropathic pain. Pain medication history was also reviewed in addition to percent pain relief. The following variables were extracted from the medical record: pain characteristics, location, cause, date of initiation of therapy, maximal tolerated dose, pain scores on the visit of optimal tolerated dose, other concurrent medications, number of months of pain before initiation of topiramate therapy, and total duration of topiramate therapy. Decrease in worst, best, and average pain was recorded, as were the development of any adverse effects. Results: Of the 13 patients on second- and third-line therapy, 53.8% had ≥ 30% decrease in worst pain; 69.2% had ≥ 30% decrease in average pain, and 53.8% had ≥ 30% decrease in best pain. Eight of 13 patients (61.5%) experienced adverse effects. Five patients discontinued (38.5%) topiramate because of adverse events. Conclusion: Because our retrospective study showed topiramate to be a beneficial second- and third-line therapy in patients with cancer who did not experience adequate pain control on previous regimens, further prospective studies are needed to establish this medication in the armamentarium of neuropathic cancer pain management.

Original languageEnglish (US)
Pages (from-to)241-246
Number of pages6
JournalSupportive Cancer Therapy
Volume4
Issue number4
DOIs
StatePublished - Sep 2007

Fingerprint

Neuralgia
Pain
Neoplasms
Therapeutics
topiramate
Maximum Tolerated Dose
Veterans
Pain Management
Palliative Care
Medical Records
Patient Care
Outpatients
Retrospective Studies
Prospective Studies

Keywords

  • Analgesia
  • Antiepileptic
  • Asthenia
  • Opioid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology

Cite this

Bendaly, E. A., Jordan, C. A., Staehler, S. S., & Rushing, D. A. (2007). Topiramate in the treatment of neuropathic pain in patients with cancer. Supportive Cancer Therapy, 4(4), 241-246. https://doi.org/10.3816/SCT.2007.n.021

Topiramate in the treatment of neuropathic pain in patients with cancer. / Bendaly, Edmond A.; Jordan, Carol A.; Staehler, Sandra S.; Rushing, Daniel A.

In: Supportive Cancer Therapy, Vol. 4, No. 4, 09.2007, p. 241-246.

Research output: Contribution to journalArticle

Bendaly, EA, Jordan, CA, Staehler, SS & Rushing, DA 2007, 'Topiramate in the treatment of neuropathic pain in patients with cancer', Supportive Cancer Therapy, vol. 4, no. 4, pp. 241-246. https://doi.org/10.3816/SCT.2007.n.021
Bendaly, Edmond A. ; Jordan, Carol A. ; Staehler, Sandra S. ; Rushing, Daniel A. / Topiramate in the treatment of neuropathic pain in patients with cancer. In: Supportive Cancer Therapy. 2007 ; Vol. 4, No. 4. pp. 241-246.
@article{cf1991abd0f94a3094b4e83d73e6fbeb,
title = "Topiramate in the treatment of neuropathic pain in patients with cancer",
abstract = "Introduction: Neuropathic pain has been reported to affect 40{\%}-50{\%} of patients with cancer. Patients and Methods: Consecutive patients selected from the outpatient/adult patient palliative care clinic of the Roudebush Veterans Affairs Medical Center and the Indiana University Palliative Clinic were reviewed. A verbal pain linear analogue assessment scale was used to assess neuropathic pain. Pain medication history was also reviewed in addition to percent pain relief. The following variables were extracted from the medical record: pain characteristics, location, cause, date of initiation of therapy, maximal tolerated dose, pain scores on the visit of optimal tolerated dose, other concurrent medications, number of months of pain before initiation of topiramate therapy, and total duration of topiramate therapy. Decrease in worst, best, and average pain was recorded, as were the development of any adverse effects. Results: Of the 13 patients on second- and third-line therapy, 53.8{\%} had ≥ 30{\%} decrease in worst pain; 69.2{\%} had ≥ 30{\%} decrease in average pain, and 53.8{\%} had ≥ 30{\%} decrease in best pain. Eight of 13 patients (61.5{\%}) experienced adverse effects. Five patients discontinued (38.5{\%}) topiramate because of adverse events. Conclusion: Because our retrospective study showed topiramate to be a beneficial second- and third-line therapy in patients with cancer who did not experience adequate pain control on previous regimens, further prospective studies are needed to establish this medication in the armamentarium of neuropathic cancer pain management.",
keywords = "Analgesia, Antiepileptic, Asthenia, Opioid",
author = "Bendaly, {Edmond A.} and Jordan, {Carol A.} and Staehler, {Sandra S.} and Rushing, {Daniel A.}",
year = "2007",
month = "9",
doi = "10.3816/SCT.2007.n.021",
language = "English (US)",
volume = "4",
pages = "241--246",
journal = "Supportive Cancer Therapy",
issn = "1543-2912",
publisher = "Cancer Information Group, LP",
number = "4",

}

TY - JOUR

T1 - Topiramate in the treatment of neuropathic pain in patients with cancer

AU - Bendaly, Edmond A.

AU - Jordan, Carol A.

AU - Staehler, Sandra S.

AU - Rushing, Daniel A.

PY - 2007/9

Y1 - 2007/9

N2 - Introduction: Neuropathic pain has been reported to affect 40%-50% of patients with cancer. Patients and Methods: Consecutive patients selected from the outpatient/adult patient palliative care clinic of the Roudebush Veterans Affairs Medical Center and the Indiana University Palliative Clinic were reviewed. A verbal pain linear analogue assessment scale was used to assess neuropathic pain. Pain medication history was also reviewed in addition to percent pain relief. The following variables were extracted from the medical record: pain characteristics, location, cause, date of initiation of therapy, maximal tolerated dose, pain scores on the visit of optimal tolerated dose, other concurrent medications, number of months of pain before initiation of topiramate therapy, and total duration of topiramate therapy. Decrease in worst, best, and average pain was recorded, as were the development of any adverse effects. Results: Of the 13 patients on second- and third-line therapy, 53.8% had ≥ 30% decrease in worst pain; 69.2% had ≥ 30% decrease in average pain, and 53.8% had ≥ 30% decrease in best pain. Eight of 13 patients (61.5%) experienced adverse effects. Five patients discontinued (38.5%) topiramate because of adverse events. Conclusion: Because our retrospective study showed topiramate to be a beneficial second- and third-line therapy in patients with cancer who did not experience adequate pain control on previous regimens, further prospective studies are needed to establish this medication in the armamentarium of neuropathic cancer pain management.

AB - Introduction: Neuropathic pain has been reported to affect 40%-50% of patients with cancer. Patients and Methods: Consecutive patients selected from the outpatient/adult patient palliative care clinic of the Roudebush Veterans Affairs Medical Center and the Indiana University Palliative Clinic were reviewed. A verbal pain linear analogue assessment scale was used to assess neuropathic pain. Pain medication history was also reviewed in addition to percent pain relief. The following variables were extracted from the medical record: pain characteristics, location, cause, date of initiation of therapy, maximal tolerated dose, pain scores on the visit of optimal tolerated dose, other concurrent medications, number of months of pain before initiation of topiramate therapy, and total duration of topiramate therapy. Decrease in worst, best, and average pain was recorded, as were the development of any adverse effects. Results: Of the 13 patients on second- and third-line therapy, 53.8% had ≥ 30% decrease in worst pain; 69.2% had ≥ 30% decrease in average pain, and 53.8% had ≥ 30% decrease in best pain. Eight of 13 patients (61.5%) experienced adverse effects. Five patients discontinued (38.5%) topiramate because of adverse events. Conclusion: Because our retrospective study showed topiramate to be a beneficial second- and third-line therapy in patients with cancer who did not experience adequate pain control on previous regimens, further prospective studies are needed to establish this medication in the armamentarium of neuropathic cancer pain management.

KW - Analgesia

KW - Antiepileptic

KW - Asthenia

KW - Opioid

UR - http://www.scopus.com/inward/record.url?scp=35348963750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348963750&partnerID=8YFLogxK

U2 - 10.3816/SCT.2007.n.021

DO - 10.3816/SCT.2007.n.021

M3 - Article

C2 - 18632523

AN - SCOPUS:35348963750

VL - 4

SP - 241

EP - 246

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

SN - 1543-2912

IS - 4

ER -